🟢 Cue Biopharma is trading 40.69% up in pre-market after CUE-221 achieved 54% complete hive resolution

Cue Biopharma is trading 40.69% up at $52.13 after positive Phase 2 results for CUE-221 in chronic spontaneous urticaria.

• The highest dose produced 54% complete hive resolution at week 12 versus 11% for placebo and 41% for omalizumab; benefits were maintained after treatment.
• CUE-221 met primary and key secondary efficacy endpoints, with a favorable safety profile and no treatment-related serious adverse events.
• Plans Phase 2b/3 development; webcast held September 21, 2026. Broader markets were positive, but company-specific data was the clearer catalyst.